Lansdowne Partners (Uk) LLP Moderna, Inc. Transaction History

Lansdowne Partners (Uk) LLP

$862 Million
Q2 2024

A detailed history of Lansdowne Partners (Uk) LLP transactions in Moderna, Inc. stock. As of the latest transaction made, Lansdowne Partners (Uk) LLP holds 20,500 shares of MRNA stock, worth $1.29 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares

20,500

Previous 36,000 43.06%

Holding current value

$1.29 Million

Previous $3.84 Million 36.55%

% of portfolio

0.28%

Previous 0.35%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$101.21 - $166.61 $1.57 Million - $2.58 Million	-15,500 Reduced 43.06%	20,500 $2.43 Million
Q1 2024 May 14, 2024	SELL	$85.37 - $115.44 $1.88 Million - $2.54 Million	-22,000 Reduced 37.93%	36,000 $3.84 Million
Q3 2023 Nov 13, 2023	BUY	$96.41 - $126.61 $2.17 Million - $2.85 Million	22,500 Added 63.38%	58,000 $5.99 Million
Q2 2023 Aug 11, 2023	SELL	$118.5 - $160.53 $237,000 - $321,060	-2,000 Reduced 5.33%	35,500 $4.31 Million
Q1 2023 May 12, 2023	BUY	$135.66 - $197.02 $203,490 - $295,530	1,500 Added 4.17%	37,500 $5.76 Million
Q4 2022 Feb 10, 2023	BUY	$118.38 - $210.04 $858,255 - $1.52 Million	7,250 Added 25.22%	36,000 $6.47 Million
Q3 2022 Nov 10, 2022	SELL	$118.07 - $194.18 $1.98 Million - $3.25 Million	-16,750 Reduced 36.81%	28,750 $3.4 Million
Q2 2022 Aug 12, 2022	BUY	$117.13 - $176.59 $1.7 Million - $2.56 Million	14,500 Added 46.77%	45,500 $6.5 Million
Q1 2022 May 16, 2022	BUY	$126.46 - $235.05 $3.92 Million - $7.29 Million	31,000 New	31,000 $5.34 Million

Others Institutions Holding MRNA

# of Institutions

1,114

Shares Held

241M

Call Options Held

9.26M

Put Options Held

12.1M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $24.7B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lansdowne Partners (Uk) LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lansdowne Partners (Uk) LLP with notifications on news.

Account

Lansdowne Partners (Uk) LLP Moderna, Inc. Transaction History